Literature DB >> 9314871

Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina.

S B Mostad1, J Overbaugh, D M DeVange, M J Welch, B Chohan, K Mandaliya, P Nyange, H L Martin, J Ndinya-Achola, J J Bwayo, J K Kreiss.   

Abstract

BACKGROUND: Factors that influence shedding of HIV-1 infected cells in cervical and vaginal secretions may be important determinants of sexual and vertical transmission of the virus. We investigated whether hormonal contraceptive use, vitamin A deficiency, and other variables were risk factors for cervical and vaginal shedding of HIV-infected cells.
METHODS: Between December, 1994, and April, 1996, women who attended a municipal sexually transmitted diseases (STDs) clinic in Mombasa, Kenya, and had previously tested positive for HIV-1, were invited to take part in our cross-sectional study. Cervical and vaginal secretions from 318 women were evaluated for the presence of HIV-1 infected cells by PCR amplification of gag DNA sequences.
FINDINGS: HIV-1 infected cells were detected in 51% of endocervical and 14% of vaginal-swab specimens. Both cervical and vaginal shedding of HIV-1 infected cells were highly associated with CD4 lymphocyte depletion (p = 0.00001 and p = 0.003, respectively). After adjustment for CD4 count, cervical proviral shedding was significantly associated with use of depot medroxyprogesterone acetate (odds ratio 2.9, 95% CI 1.5-5.7), and with use of low-dose and high-dose oral contraceptive pills (3.8, 1.4-9.9 and 12.3, 1.5-101, respectively). Vitamin A deficiency was highly predictive of vaginal HIV-1 DNA shedding. After adjustment for CD4 count, severe vitamin A deficiency, moderate deficiency, and low normal vitamin A status were associated with 12.9, 8.0, and 4.9-fold increased odds of vaginal shedding, respectively. Gonococcal cervicitis (3.1, 1.1-9.8) and vaginal candidiasis (2.6, 1.2-5.4) were also correlated with significant increases in HIV-1 DNA detection, but Chlamydia trachomatis and Trichomonas vaginalis were not.
INTERPRETATION: Our study documents several novel correlates of HIV-1 shedding in cervical and vaginal secretions, most notably hormonal contraceptive use and vitamin A deficiency. These factors may be important determinants of sexual or vertical transmission of HIV-1 and are of public health importance because they are easily modified by simple interventions.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Africa; Africa South Of The Sahara; Biology; Cervical Effects; Cervix; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Correlation Studies; Deficiency Diseases; Depo-provera; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Family Planning; Genitalia; Genitalia, Female; Hiv Infections--transmission; Infections; Kenya; Medroxyprogesterone Acetate; Nutrition Disorders; Oral Contraceptives; Oral Contraceptives, Combined; Physiology; Reproductive Tract Infections; Research Methodology; Research Report; Risk Factors; Sexually Transmitted Diseases; Statistical Studies; Studies; Urogenital System; Uterus; Vagina; Viral Diseases; Vitamin A; Vitamins

Mesh:

Substances:

Year:  1997        PMID: 9314871     DOI: 10.1016/S0140-6736(97)04240-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

1.  Efforts to Control Sexually Transmitted Diseases As a Means to Limit HIV Transmission: Pros and Cons.

Authors:  Gina Dallabetta; Madaline Feinberg
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

2.  Comparison of techniques for HIV-1 RNA detection and quantitation in cervicovaginal secretions.

Authors:  G C John; H Sheppard; D Mbori-Ngacha; R Nduati; D Maron; M Reiner; J Kreiss
Journal:  J Acquir Immune Defic Syndr       Date:  2001-02-01       Impact factor: 3.731

3.  Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment.

Authors:  Susan M Graham; Linnet Masese; Ruth Gitau; Zahra Jalalian-Lechak; Barbra A Richardson; Norbert Peshu; Kishor Mandaliya; James N Kiarie; Walter Jaoko; Jeckoniah Ndinya-Achola; Julie Overbaugh; R Scott McClelland
Journal:  J Infect Dis       Date:  2010-10-05       Impact factor: 5.226

4.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

5.  Efforts to Control Sexually Transmitted Infections As a Means to Limit HIV Transmission: What Is the Evidence?

Authors:  Gina Dallabetta; Graham Neilsen
Journal:  Curr Infect Dis Rep       Date:  2005-01       Impact factor: 3.725

6.  Sexually transmitted infections among HIV-infected adults in HIV care programs in Kenya: a national sample of HIV clinics.

Authors:  Benson Singa; Sara Nelson Glick; Naomi Bock; Judd Walson; Linda Chaba; James Odek; R Scott McClelland; Gaston Djomand; Hongjiang Gao; Grace John-Stewart
Journal:  Sex Transm Dis       Date:  2013-02       Impact factor: 2.830

7.  Neonatal herpes simplex virus infection.

Authors:  Thomas L Cherpes; Dean B Matthews; Samantha A Maryak
Journal:  Clin Obstet Gynecol       Date:  2012-12       Impact factor: 2.190

Review 8.  Contraception for HIV-Infected Adolescents.

Authors:  Athena P Kourtis; Ayesha Mirza
Journal:  Pediatrics       Date:  2016-09       Impact factor: 7.124

Review 9.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

10.  Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative.

Authors:  Elizabeth M Stringer; Mark Giganti; Rosalind J Carter; Wafaa El-Sadr; Elaine J Abrams; Jeffrey Sa Stringer
Journal:  AIDS       Date:  2009-11       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.